Through searching and evaluating the evidence on advanced prostate cancer, we found that different types of androgen deprivation had similar effect, and immediate androgen deprivation had survival benefit. For the patient with hormone-refractory prostate cancer, therapies including mitoxantrone, prednisone, docetaxel and surmine were more effective. Strontium-89 provided more effective pain relief than external beam radiation. And bisphophonate had no effect. Antiandrogen withdrawal suggested prostate specific antigen would decline, but the clinical outcome wasn’t reported.
目的 應用基于鏈式方程的填補方法處理醫學研究中的數據缺失，并以填補后完全數據構建聯合指標的logistic判別函數，判斷其在前列腺癌的預測診斷中的應用價值。 方法 采用模擬研究，針對現實數據缺失情況模擬不同填補集結果，并以此對現實數據進行填補，以完整數據構建logistic判別，進行分析預測。 結果 填補結果隨著填補次數的增加而逐漸接近真實值并趨于穩定。聯合年齡、血清前列腺特異性抗原值、血流阻力指數及經直腸前列腺超聲檢查指標的logistic判別分析結果的靈敏度為82.39%，特異度為74.86%。 結論 聯合指標分析可提高前列腺癌的診斷預測水平，以減輕患者穿刺痛苦。
Image fusion currently plays an important role in the diagnosis of prostate cancer (PCa). Selecting and developing a good image fusion algorithm is the core task of achieving image fusion, which determines whether the fusion image obtained is of good quality and can meet the actual needs of clinical application. In recent years, it has become one of the research hotspots of medical image fusion. In order to make a comprehensive study on the methods of medical image fusion, this paper reviewed the relevant literature published at home and abroad in recent years. Image fusion technologies were classified, and image fusion algorithms were divided into traditional fusion algorithms and deep learning (DL) fusion algorithms. The principles and workflow of some algorithms were analyzed and compared, their advantages and disadvantages were summarized, and relevant medical image data sets were introduced. Finally, the future development trend of medical image fusion algorithm was prospected, and the development direction of medical image fusion technology for the diagnosis of prostate cancer and other major diseases was pointed out.
Objective To investigate the application of the dynamic contrast enhanced MRI (DCE-MRI ) combined with magnetic resonance spectroscopy (MRS) in the diagnosis of prostate cancer. Method A total of 60 patients with prostate cancer and 60 patients with benign prostatic hyperplasia diagnoses in Sichuan Cancer Hospital from January 2011 to January 2014 were included as prostate cancer group and proliferative group respectively. Sixty healthy individuals during the same period were included as the control group. We used Siemens Avanto 1.5 T high field superconducting MRI for DCE-MRI scan and MRS scan. After the MRS scan was finished, we used the workstation spectroscopy tab spectral analysis. Eventually we got the crest lines of prostate metabolites choline (Cho), creatine (Cr) and citrate (Cit). Then we calculated Cho/Cit, (Cho+Cr)/Cit and their average. Results Comparing the signal value in 21 seconds, 1 minute, 2 minutes of DCE-MRI, the differences among the three groups were statistically significant (P<0.05). Comparing the results of spectral analysis, the differences among the three groups were statistically significant (P<0.05). The sensitivity was 89.67%, the specificity was 95.45% and the accuracy was 94.34% when using DCE-MRI combined with MRS. Conclusion DCE-MRI combined with MRS greatly improves the sensitivity, specificity and accuracy of the diagnosis of prostate cancer; it has a great application value in the diagnosis of prostate cancer.
Radionuclides can be labeled on biomolecules with specific binding ability. By binding with specific targets of tumors, particles such as α or β emitted by the radionuclides will specifically irradiate tumors and produce ionizing radiation effects, resulting in cell senescence and death within the irradiation range, achieving tumor treatment results, and this way has little impact on surrounding normal tissues. Lutetium-177 (177Lu) can emit γ rays for CT imaging, and can also emit β rays for tumor treatment, so 177Lu is now one of the radionuclides that can be used for integrated diagnosis and treatment. This review summarizes the clinical application of 177Lu in several solid tumors, in conjunction with currently published research.
ObjectivesTo systematically review the association between the variants of HNF1B gene and the risk of prostate cancer.MethodsPubMed, EMbase, The Cochrane Library, CNKI, CBM and WanFang Data databases were electronically searched to collect case-control studies on the association between the variants of HNF1B gene and risk of prostate cancer from inception to December, 2017. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Meta-analysis was then performed using Stata 14.0 software.ResultsA total of 15 case-control studies involving 30 532 patients and 38 832 controls were included. The results of meta-analysis showed that: there was a strong significant association between rs4430796 variants (Gvs.A: OR=0.802, 95%CI 0.784 to 0.821, P<0.001; GGvs.AA: OR=0.659, 95%CI 0.606 to 0.717, P<0.001; AGvs.AA: OR=0.762, 95%CI 0.714 to 0.814, P<0.001), rs11649743 variants (Avs.G: OR=0.875, 95%CI 0.820 to 0.941, P<0.001; AAvs.GG: OR=0.669, 95%CI 0.564 to 0.792, P<0.001; AGvs.GG: OR=0.855, 95%CI 0.798 to 0.916, P<0.001), rs7501939 variants (Avs.G: OR=0.833, 95%CI 0.807 to 0.859, P<0.001), rs3760511 variants (Avs.C: OR=0.834, 95%CI 0.803 to 0.868, P<0.001) and risk of prostate cancer.ConclusionsCurrent evidence shows that HNF1B gene variants are associated with risk of prostate cancer. Due to limited quantity and quality of the included studies, more high quality studies are required to verify the above conclusion.
Prostate cancer ranks second among the causes of death of malignant tumors in middle-aged and elderly men. A considerable number of patients are not easily detected in early-stage prostate cancer. Although traditional imaging examinations are of high value in the diagnosis and staging of prostate cancer, they also have certain limitations. With the development of nuclear medicine instruments and molecular probes, molecular imaging is playing an increasingly important role in the diagnosis and treatment of prostate cancer. Positron emission tomography and computed tomography (PET/CT) using prostate-specific membrane antigen (PSMA) as a probe has gained increasing recognition. This article will review the latest progress in the application of PET/CT using probes for targeting PSMA to imaging and treatment of prostate cancer, in order to provide a theoretical basis for the application of probes for targeting PSMA in the diagnosis and treatment of prostate cancer.
【摘要】 目的 探討在恥骨后前列腺癌根治術中尿控功能和性功能保護的手術技巧和療效。 方法 2001年8月-2010年1月，行恥骨后前列腺癌根治術21例，其中2例經腹腔鏡。所有患者均早期控制縫扎背靜脈復合體，并妥善處理前列腺尖和尿道。21例通過保護控尿神經、尿道橫紋括約肌，保護了尿控功能；17例通過保留神經血管束技術（12例保留雙側，5例保留一側）保護性功能。 結果 手術均成功完成，無圍手術期嚴重并發癥。2周拔出尿管后，排尿通暢，無尿道狹窄。術后3、12個月內恢復尿控能力患者分別為6、13例，持續性輕-中度尿失禁2例。21例患者中，術前勃起功能正常；術中保留神經血管束17例，術后3、12個月內勃起功能恢復分別為2、8例，4例勃起功能減弱，3例不能勃起。術后病理報告均為前列腺癌，未侵及精囊、膀胱頸、雙側淋巴結陰性。后尿道切緣陽性1例。術后6、24、54個月各有1例出現生化復發。 結論 手術精細解剖并注意技巧，可有效保護尿控功能和性功能，并達到腫瘤根治的療效。【Abstract】 Objective To evaluate the surgical technique for the protection of urinary continence and erectile function in radical prostatectomy for prostate cancer and observe its clinical efficacy. Methods Twenty-one patients with prostate cancer had undergone radical prostatectomy during August 2001 to January 2010, in which two patients were operated through extraperitoneal laparoscope. Dorsal vein complex was sewed and ligated at early stage of surgery and prostate apex along with urethra were appropriately handled in all patients. By a serial measures consisting of protection for continence nerve and striated urethral sphincter, the function of urinary continence was managed to be spared in twenty-one patients, erectile function was managed to be spared through reservation of neurovascular bundle in seventeen patients (Bilateral neurovascular bundles were reserved in twelve patients, unilateral neurovascular bundle was reserved in five patients). Results All surgeries were successful without severe perioperative complications. The catheters were removed fourteen days after surgery in all patients, and it was observed that micturition was fluent in twenty-one patients. Functional recovery of urinary continence occurred within three months after surgery in six patients and twleve months in thirteen patients, continuous mild-moderate incontinece occurred in two patients. Erectile function was normal before surgery and neurovascular bundle was reserved during surgery in seventeen patients. The recovery of erectile function occurred within three months after surgery in two patients and twelve months in eight patients, erectile function was impaired in four patients, erectile dysfunction occurred in three patients, pathological diagnosis indicated prostate adenocarcinoma in all cases, while seminal vesicle and bladder neck were not invaded and bilateral pelvic lymph nodes were not metastasized, moreover, the pathological diagnosis of resected edge of posterior urethra was positive in one patient. One patient of bio-chemical recurrence occurred respectively within six months, twenty-four months and fifty-four months after surgery. Conclusion During radical prostatectomy for prostate cancer, delicately anatomizing and appropriate surgical technique could effectively protect erectile function and urinary continence and consequently achieve radical resection of tumor at the same time.
Prostate cancer is the most common malignant tumor in male urinary system, and the morbidity and mortality rate are increasing year by year. Traditional imaging examinations have some limitations in the diagnosis of prostate cancer, and the advent of molecular imaging probes and imaging technology have provided new ideas for the integration of diagnosis and treatment of prostate cancer. In recent years, prostate-specific membrane antigen (PSMA) has attracted much attention as a target for imaging and treatment of prostate cancer. PSMA ligand positron emission tomography (PET) has important reference value in the diagnosis, initial staging, detection of biochemical recurrence and metastasis, clinical decision-making guidance and efficacy evaluation of prostate cancer. This article briefly reviews the clinical research and application progress on PSMA ligand PET imaging in prostate cancer in recent years, so as to raise the efficiency of clinical applications.